Ty-jour t1 - 抗IL-5 mepolizumab最小地影响严重哮喘JF中的残留血液粒细胞 - 欧洲呼吸杂志Jo - Eur Respir J Do - 10.1183 / 13993003 - 2100935-2021 SP - 2100935-2021 SP - 2100935 Au - 范·普斯特，格伦奥尔斯·杰尔森，约瑟夫Au - Jacobs，Nathalie Au - Henket，Monique Au - Louis，Renaud Au - Schleich，Florence Au - 局，Fabrice Au - Desmet，Christophe J. Y1 - 2021/01/01/01/01 UR - //www.qdcxjkg.com/ Content/early/2021/07/29/13993003.00935-2021.Abstract N2 - 抗细胞因子白细胞介素（IL）-5的中和抗体已广泛用于控制严重的嗜酸性哮喘。值得注意的是，接受中和抗IL5生物疗法的患者保留了非常稳定的残留血液粒细胞。尚未研究这些残留的嗜酸性粒细胞是否赋予特定的生物活性，但在预测IL5中和患者中的潜在长期影响方面尚不重要。为了解决IL5耗竭对残留嗜酸性粒细胞的影响，我们使用了对比较的RNA测序方法，并将嗜酸性粒细胞的基因表达程序与IL5耗尽或IL5-Replete人或鼠宿主的基因表达程序进行了比较，并且在体内稳态及以下用嗜酸性粒细胞激活警报IL33的体外刺激。我们将用抗IL5 Mepolizumab疗法治疗的严重过敏性嗜酸性哮喘患者与接受抗IgE omalizumab治疗的健康对照治疗和患有哮喘患者的血液嗜酸性患者。我们对来自遗传缺陷或不适用于IL5的小鼠的骨髓嗜酸性粒细胞的比较。我们报告说，IL5可用性的限制在Mepolizumab治疗的患者或IL5缺陷小鼠中稳态残留嗜酸性粒细胞中的任何可检测的转录反应，并且只影响了对IL33的响应的少数基因。 Together, these results support the notion that treatment with IL5 neutralising antibodies spares a pool of circulating residual eosinophils largely resembling those of healthy individuals.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Glenn Van Hulst has nothing to disclose.Conflict of interest: J. Jorssen reports PhD student scholarship from Fonds de la Recherche scientifique (FRS)-FNRS (Belgium).Conflict of interest: N. Jacobs reports consulting fees and lecture fees from GSK, outside the submitted work.Conflict of interest: Monique Henket has nothing to disclose.Conflict of interest: L. Renaud reports grants from GSK, AZ, Novartis, Chiesi and Teva; royalties from patent AU2016328384, CA2997506, EP 3337393, US2020345266; consulting fees and lecture payments from GSK, AZ, Novartis, Sanofi and Chiesi, outside the submitted work.Conflict of interest: F. Schleich reports grants from GSK, Astrazeneca, Teva, Chiesi and Novartis; consulting fees from GSK, Astrazeneca, Amgen, Chiesi and Novartis; lecture payments from GSK, Astrazeneca, Teva, Chiesi and Novartis, outside the submitted work.Conflict of interest: Fabrice Bureau has nothing to disclose.Conflict of interest: C. Desmet reports salary from Fonds de la Reherche Scientifique – FNRS (Belgium), during the submitted work; consulting fees in Advisory Board on eosinophil research from AstraZeneca; lecture fees for presentation at several scientific symposia in Europe on our research on eosinophils from GSK, outside the submitted work. ER -